You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A simple assay system for rapid detection of circulating tumor cells

    SBC: TELOVISION, LLC            Topic: NCI

    DESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A smart needle guide template for MRI-guided transperineal prostate biopsy

    SBC: Physical Sciences Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Physical Sciences Inc. (PSI) and the Surgical Navigation and Robotics Laboratory (SNR) at Brigham and Women's Hospital (BWH) propose to develop and test a Smart Template to guide transperineal targeted prostate biopsiesand subsequent therapy under magnetic resonance imaging (MRI). The project aims to solve the problem of poor diagnostic yield in prostate b ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. AutoRegister: A system for enhancing the accuracy of tumor change detection

    SBC: CORTICOMETRICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This project proposes to build an integrated software-based system for enhancing the accuracy of tumor change detection. The intent of the system, called AutoRegister, which is to be deployed on a clinical magnetic resonance imaging (MRI) scanner platform, is to automate the alignment of a patient's brain scan with that of a prior scan, such that subseque ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Brain penetrant Hsp90 inhibitors for Alzheimer's disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION provided by applicant Neurodegeneration in Alzheimerandapos s disease AD may result from deposition of A as plaques in brain tissue However less effort has been made to elucidate the role of tau containing neurofibrillary tangles NFTs in AD Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neu ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Developing Inhibitors of the STARS/SRF Pathway for Treatment of Type 2 Diabetes

    SBC: Jenesis Biosciences LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Type 2 diabetes (T2D) has reached epidemic proportions in the United States, affecting an estimated 8.3% of the population. Unfortunately, the majority of individuals with diabetes continue to have suboptimal control ofglucose, therefore new and improved approaches to prevention and treatment are sorely needed. Dr. Mary Elizabeth Patti's laboratory at the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a clinical hemoglobin modulator

    SBC: Phoenicia Biosciences, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant The thalassemias and sickle cell disease are serious genetic blood diseases which are WHO designated as a growing global health burden The disorders decrease production or alter structure of the b chain of adult hemoglobin A and are characterized by anemia chronic organ damage and early mortality HbF is another type of normal hemoglobin which is suppres ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Compounds for the Prevention and Treatment of Rhabdomyolysis

    SBC: Virtual Drug Development Inc.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of small near-infrared laser system capable of improving immune respo

    SBC: SEMINEX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make va ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government